Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2022-03-07 02:49:05 UTC |
---|
HMDB ID | HMDB0000653 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Cholesterol sulfate |
---|
Description | Cholesterol sulfate, or cholest-5-en-3beta-ol sulfate, is an endogenous steroid and the C3beta sulfate ester of cholesterol. It is formed from cholesterol by steroid sulfotransferases (SSTs) such as SULT2B1b (also known as cholesterol sulfotransferase) and is converted back into cholesterol by steroid sulfatase (STS). Accumulation of cholesterol sulfate in the skin is implicated in the pathophysiology of X-linked ichthyosis, a congenital disorder in which STS is non-functional and the body cannot convert cholesterol sulfate back into cholesterol. Cholesterol sulfate is quantitatively the most important known sterol sulfate in human plasma, where it is present in a concentration that overlaps that of the other abundant circulating steroid sulfate, dehydroepiandrosterone (DHEA) sulfate (PMID 12730293 ). Cholesterol sulfate has a stabilizing function on the membrane, supports platelet adhesion and is involved in signal transduction (PMID 12730293 ). It plays a role in protecting erythrocytes from osmotic lysis and regulating sperm capacitation. Cholesterol sulfate can regulate the activity of serine proteases, e.g., those involved in blood clotting, fibrinolysis, and epidermal cell adhesion (PMID 12730293 ). As a result of its ability to regulate the activity of selective protein kinase C isoforms and modulate the specificity of phosphatidylinositol 3-kinase, cholesterol sulfate is involved in signal transduction (PMID 12730293 ). Cholesterol sulfate functions in keratinocyte differentiation, inducing genes that encode for key components involved in development of the barrier (PMID 12730293 ). |
---|
Structure | [H][C@@]12CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OS(O)(=O)=O InChI=1S/C27H46O4S/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(31-32(28,29)30)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25H,6-8,10-17H2,1-5H3,(H,28,29,30)/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1 |
---|
Synonyms | Value | Source |
---|
CHOLEST-5-en-3-yl hydrogen sulfATE | ChEBI | Cholest-5-en-3beta-ol sulfate | ChEBI | Cholesterol 3-sulfate | ChEBI | Cholesterol 3-sulphate | ChEBI | Cholesterol hydrogen sulfate | ChEBI | Cholesterol hydrogen sulphate | ChEBI | Cholesterol sulphate | ChEBI | Cholesteryl sulfate | ChEBI | Cholesteryl sulphate | ChEBI | CHOLEST-5-en-3-yl hydrogen sulfuric acid | Generator | CHOLEST-5-en-3-yl hydrogen sulphate | Generator | CHOLEST-5-en-3-yl hydrogen sulphuric acid | Generator | Cholest-5-en-3b-ol sulfate | Generator | Cholest-5-en-3b-ol sulfuric acid | Generator | Cholest-5-en-3b-ol sulphate | Generator | Cholest-5-en-3b-ol sulphuric acid | Generator | Cholest-5-en-3beta-ol sulfuric acid | Generator | Cholest-5-en-3beta-ol sulphate | Generator | Cholest-5-en-3beta-ol sulphuric acid | Generator | Cholest-5-en-3β-ol sulfate | Generator | Cholest-5-en-3β-ol sulfuric acid | Generator | Cholest-5-en-3β-ol sulphate | Generator | Cholest-5-en-3β-ol sulphuric acid | Generator | Cholesterol 3-sulfuric acid | Generator | Cholesterol 3-sulphuric acid | Generator | Cholesterol hydrogen sulfuric acid | Generator | Cholesterol hydrogen sulphuric acid | Generator | Cholesterol sulfuric acid | Generator | Cholesterol sulphuric acid | Generator | Cholesteryl sulfuric acid | Generator | Cholesteryl sulphuric acid | Generator | 5-Cholesten-3b-yl sulfate | HMDB | 5-Cholesten-3b-yl sulphate | HMDB | Cholesteryl sulfate, sodium salt, (3beta)-isomer | MeSH, HMDB | Cholesteryl sulfate, ammonium salt, (3beta)-isomer | MeSH, HMDB | Cholesteryl sulfate, sodium salt, 26-(14)C-labeled | MeSH, HMDB | Cholesteryl sulfate, 3H-labeled, (3beta)-isomer | MeSH, HMDB | Cholesteryl sulfate, potassium salt, (3beta)-isomer | MeSH, HMDB |
|
---|
Chemical Formula | C27H46O4S |
---|
Average Molecular Weight | 466.717 |
---|
Monoisotopic Molecular Weight | 466.31168065 |
---|
IUPAC Name | [(1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-5-yl]oxidanesulfonic acid |
---|
Traditional Name | [(1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-5-yl]oxidanesulfonic acid |
---|
CAS Registry Number | 1256-86-6 |
---|
SMILES | [H][C@@]12CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OS(O)(=O)=O |
---|
InChI Identifier | InChI=1S/C27H46O4S/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(31-32(28,29)30)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25H,6-8,10-17H2,1-5H3,(H,28,29,30)/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1 |
---|
InChI Key | BHYOQNUELFTYRT-DPAQBDIFSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as cholesterols and derivatives. Cholesterols and derivatives are compounds containing a 3-hydroxylated cholestane core. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Cholestane steroids |
---|
Direct Parent | Cholesterols and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Cholesterol
- Sulfated steroid skeleton
- Delta-5-steroid
- Sulfuric acid ester
- Alkyl sulfate
- Sulfate-ester
- Sulfuric acid monoester
- Organic sulfuric acid or derivatives
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 9.82 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 29.197 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.97 minutes | 32390414 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 4016.6 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 871.2 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 336.6 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 373.4 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 795.2 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1342.9 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1277.0 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 110.8 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 2327.8 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 759.0 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2517.5 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 799.2 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 653.3 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 437.7 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 736.7 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Cholesterol sulfate,1TMS,isomer #1 | CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@@]21C | 3649.6 | Semi standard non polar | 33892256 | Cholesterol sulfate,1TMS,isomer #1 | CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@@]21C | 3661.7 | Standard non polar | 33892256 | Cholesterol sulfate,1TMS,isomer #1 | CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@@]21C | 4229.5 | Standard polar | 33892256 | Cholesterol sulfate,1TBDMS,isomer #1 | CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@@]21C | 3854.9 | Semi standard non polar | 33892256 | Cholesterol sulfate,1TBDMS,isomer #1 | CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@@]21C | 3959.3 | Standard non polar | 33892256 | Cholesterol sulfate,1TBDMS,isomer #1 | CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@@]21C | 4308.8 | Standard polar | 33892256 |
|
---|
General References | - Mason JI, Hemsell PG: Cholesterol sulfate metabolism in human fetal adrenal mitochondria. Endocrinology. 1982 Jul;111(1):208-13. [PubMed:7084110 ]
- Marinkovic-Ilsen A, Wolthers BG, Jansen G, de Bruijn HW, van der Loos C: Early diagnosis of recessive X-linked ichthyosis: elevation of cholesterol sulfate levels in placental sulfatase deficiency before the onset of skin symptoms. Pediatr Dermatol. 1985 Nov;3(1):59-64. [PubMed:4070088 ]
- Bedin M, Pointis G: [Steroid sulfatase and placental deficiency. Current data as instigators of new research]. Ann Endocrinol (Paris). 1987;48(4):323-33. [PubMed:3477995 ]
- Strott CA, Higashi Y: Cholesterol sulfate in human physiology: what's it all about? J Lipid Res. 2003 Jul;44(7):1268-78. Epub 2003 May 1. [PubMed:12730293 ]
- Serizawa S, Nagai T, Sato Y: Simplified method of determination of serum cholesterol sulfate by reverse phase thin-layer chromatography. J Invest Dermatol. 1987 Dec;89(6):580-7. [PubMed:2960747 ]
- Sion B, Grizard G, Boucher D: Quantitative analysis of desmosterol, cholesterol and cholesterol sulfate in semen by high-performance liquid chromatography. J Chromatogr A. 2001 Nov 23;935(1-2):259-65. [PubMed:11762778 ]
- Zettersten E, Man MQ, Sato J, Denda M, Farrell A, Ghadially R, Williams ML, Feingold KR, Elias PM: Recessive x-linked ichthyosis: role of cholesterol-sulfate accumulation in the barrier abnormality. J Invest Dermatol. 1998 Nov;111(5):784-90. [PubMed:9804339 ]
- Serizawa S, Nagai T, Ito M, Sato Y: Simplified determination of serum cholesterol sulfate by gas-liquid chromatography combined with cyclohexylsilane-bonded phase column purification. Arch Dermatol Res. 1989;281(6):411-6. [PubMed:2531994 ]
- Marinkovic-Ilsen A, van den Ende A, Wolthers BG: Excretion of (sulfated) steroids in the urine and excretion of cholesterol sulfate in the feces of boys with recessive X-linked ichthyosis. Arch Dermatol Res. 1984;276(6):364-9. [PubMed:6542768 ]
- Iwamori M, Suzuki H, Kimura T, Iwamori Y: Shedding of sulfated lipids into gastric fluid and inhibition of pancreatic DNase I by cholesterol sulfate in concert with bile acids. Biochim Biophys Acta. 2000 Sep 27;1487(2-3):268-74. [PubMed:11018478 ]
|
---|